-transparent.png){kind=logo}
Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily X 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
January 1980,
Cancer chemotherapy and pharmacology,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
October 1985,
American journal of clinical oncology,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
May 1978,
European journal of cancer,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
April 1985,
Cancer treatment reports,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
April 1992,
Investigational new drugs,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
September 1985,
Cancer treatment reports,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
August 1982,
Cancer treatment reports,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
September 1988,
Investigational new drugs,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
November 1982,
Cancer treatment reports,
D S Ettinger, and
R Day, and
J A Ferraro, and
J C Ruckdeschel, and
J E Woll, and
R H Creech, and
S E Vogl
February 1991,
Investigational new drugs,
